PFE 10-Q Quarterly Reports

Pfizer Inc. reported a decrease in total revenues for the third quarter of 2025, down 6% to $16.7 billion, primarily due to lower sales of Paxlovid and Comirnaty. This decline was partially offset by growth in key products like Eliquis and the Vyndaqel family. Net income attributable to Pfizer Inc. common shareholders for the quarter was $3.54 billion, a decrease from $4.47 billion in the prior year's third quarter, resulting in diluted EPS of $0.62 compared to $0.78. For the nine-month period ended September 28, 2025, total revenues also saw a slight decrease of 2% to $45.0 billion. Net income attributable to common shareholders increased to $9.42 billion from $7.62 billion in the prior year's nine-month period, with diluted EPS rising to $1.65 from $1.34. The company highlighted significant investments in R&D, including a $1.35 billion charge for an in-licensing agreement with 3SBio. Pfizer is actively managing its cost base through realignment and manufacturing optimization programs, aiming for significant net cost savings. The company also announced a proposed acquisition of Metsera for approximately $4.9 billion, subject to closing conditions.

Pfizer Inc. reported strong financial results for the second quarter and first six months of 2025, with total revenues increasing by 10% and 1% respectively, driven by operational growth in key therapeutic areas. Net income attributable to Pfizer Inc. common shareholders surged to $2.91 billion ($0.51 per diluted share) for the quarter and $5.88 billion ($1.03 per diluted share) for the year-to-date period, a significant improvement compared to the prior year. The company's cost-reduction initiatives are demonstrating positive impacts, with Selling, Informational, and Administrative expenses decreasing year-over-year. These results reflect robust performance across its Biopharma segment, with notable contributions from products like the Vyndaqel family, Padcev, Xtandi, and Comirnaty, despite some headwinds from increased manufacturer discounts due to the IRA Medicare Part D Redesign and competitive pressures on certain established products. Pfizer is actively managing its operational efficiency and strategic investments, as evidenced by its ongoing cost realignment and manufacturing optimization programs. The company also made significant business development moves, including an in-licensing agreement for a bispecific antibody targeting PD-1 and VEGF, demonstrating a commitment to expanding its pipeline. The company's financial position remains strong, with substantial cash and equivalents and prudent capital allocation strategies, including dividend payments and share repurchases. While patent expiries and evolving regulatory landscapes, particularly concerning drug pricing, present ongoing challenges, Pfizer's diversified portfolio and strategic investments position it to navigate these complexities.

Pfizer Inc. reported total revenues of $13.7 billion for the first quarter ended March 30, 2025, a decrease of 8% compared to $14.9 billion in the prior year period. This decline was primarily attributed to a significant drop in Paxlovid sales, which were impacted by lower COVID-19 infections and reduced government purchases, as well as the non-recurrence of a favorable revenue adjustment recognized in the prior year. Despite the overall revenue decrease, operational improvements and growth in key therapeutic areas like the Vyndaqel family, Padcev, and Lorbrena provided some offset. Net income attributable to Pfizer Inc. common shareholders was $2.97 billion, or $0.52 per diluted share, compared to $3.12 billion, or $0.55 per diluted share, in the first quarter of 2024. The decrease in profitability was influenced by lower revenues, increased restructuring charges, and higher intangible asset impairment charges. However, the company is actively managing its cost base through ongoing productivity initiatives and cost realignment programs, which are expected to yield significant savings. Pfizer also completed the sale of its remaining investment in Haleon, generating $6.3 billion in proceeds to support its capital allocation priorities.

Pfizer Inc. reported a significant increase in total revenues for the third quarter of 2024, reaching $17.7 billion, a 31% rise compared to the prior year period. This growth was primarily driven by strong performance in Paxlovid, revenues from newly acquired Seagen products, and the Vyndaqel family, which more than offset declines in other areas. The company's net income attributable to Pfizer Inc. common shareholders was $4.465 billion, a substantial improvement from a net loss in the same quarter last year, largely due to increased revenues and a significant decrease in the cost of sales. This strong financial performance reflects a strategic shift towards oncology and growth in key therapeutic areas, alongside successful integration of recent acquisitions. For the first nine months of 2024, total revenues saw a modest increase to $45.9 billion. The company continues to focus on operational efficiency and cost realignment, with significant restructuring programs underway aimed at optimizing costs and improving margins. Despite ongoing investments in research and development and integration costs from acquisitions, Pfizer demonstrated a robust recovery in profitability, with income from continuing operations before taxes showing a substantial increase year-over-year. The company maintains a strong liquidity position, supported by robust operating cash flows and access to credit facilities, positioning it to continue investing in its pipeline and delivering value to shareholders.

Pfizer Inc. (PFE) reported $13.28 billion in total revenues for the second quarter of 2024, a slight increase of 2% year-over-year, driven by operational growth from legacy Seagen products and continued demand for its Vyndaqel family and Eliquis, partially offset by declines in Comirnaty and Xeljanz. For the first six months of 2024, total revenues were $28.16 billion, down 11% year-over-year, primarily due to significant declines in Comirnaty and Paxlovid sales. The company experienced a net loss attributable to Pfizer Inc. common shareholders of $41 million for the quarter, a stark contrast to the $2.33 billion net income reported in the same period last year. This shift is largely attributable to increased restructuring charges and acquisition-related costs, unfavorable movements in equity securities, and higher net interest expenses. Despite these challenges, Pfizer is actively pursuing cost realignment and manufacturing optimization programs, signaling a focus on improving future profitability and aligning costs with evolving revenue expectations.

Pfizer Inc. (PFE) reported its first-quarter 2024 financial results, showing a notable decrease in total revenues to $14.9 billion from $18.5 billion in the prior year period, a 20% decline driven primarily by lower sales of its COVID-19 products, Comirnaty and Paxlovid. Excluding these, total revenues saw an operational increase of 11%, bolstered by the recent acquisition of Seagen, continued growth in the Vyndaqel family and Eliquis, and the launch of Abrysvo for older adults. Net income attributable to Pfizer Inc. common shareholders significantly decreased to $3.1 billion, or $0.55 per diluted share, compared to $5.5 billion, or $0.97 per diluted share, in the first quarter of 2023. The company continues to manage its cost base, announcing a multi-year enterprise-wide cost realignment program expected to yield at least $4 billion in net cost savings by 2024. Integration of the Seagen acquisition, which closed in December 2023, is ongoing and is expected to generate approximately $1 billion in annual cost synergies by 2026. Pfizer also reported a substantial decrease in operating cash flow, alongside strategic actions such as the partial sale of its Haleon investment, generating $3.5 billion in proceeds.

Pfizer Inc. reported a net loss of $2.382 billion ($0.42 per share) for the third quarter of 2023, a significant shift from the $8.608 billion net income ($1.54 per share) in the same period last year. This decline was primarily driven by a substantial decrease in revenues, largely due to lower sales of its COVID-19 products, Comirnaty and Paxlovid. While non-COVID-19 product revenues saw growth, it was not enough to offset the decline from the pandemic-era blockbusters. The company is undertaking a cost realignment program expected to deliver at least $3.5 billion in annual net cost savings, aiming to better align expenses with future revenue expectations. This program, along with ongoing restructuring efforts, reflects Pfizer's strategic focus on adapting to a post-pandemic market and investing in its future growth drivers, including the proposed acquisition of Seagen. Investors will be closely watching the successful integration of Seagen and the performance of its non-COVID-19 portfolio.

Pfizer Inc. (PFE) reported a significant decrease in revenue for the second quarter and first six months of 2023 compared to the prior year, primarily driven by lower sales of its COVID-19 products, Comirnaty and Paxlovid. Total revenues for the second quarter were $12.7 billion, down 54% year-over-year, while the six-month revenue was $31.0 billion, a 42% decrease. Excluding these COVID-19 products, Pfizer saw operational revenue growth of 5% in both periods, fueled by recently acquired products and strong performance in its Vyndaqel family. The company's strategic focus is shifting, as evidenced by the pending acquisition of Seagen, a move to bolster its oncology portfolio. Despite the top-line decline due to the expected phasing out of COVID-19 related sales, Pfizer's underlying business demonstrates resilience with growth in key non-COVID-19 products. The company is actively managing its portfolio and investing in R&D, with a significant upcoming event being the proposed acquisition of Seagen, which is expected to be financed through a combination of debt and existing cash. Investors should monitor the integration of acquired assets and the impact of ongoing patent expirations on future revenue streams.

Pfizer Inc. reported first-quarter 2023 revenues of $18.3 billion, a 29% decrease compared to $25.7 billion in the first quarter of 2022. This decline was primarily driven by lower sales of Comirnaty, partially offset by growth in Paxlovid. Excluding COVID-19 products, revenues increased by 5% operationally, driven by contributions from recently acquired products and continued strength in the company's non-COVID-19 portfolio such as Eliquis and the Vyndaqel family. Net income attributable to Pfizer Inc. common shareholders decreased to $5.54 billion ($0.97 per diluted share) from $7.86 billion ($1.37 per diluted share) in the prior year's quarter. The company also announced a significant proposed acquisition of Seagen for approximately $43 billion, which is expected to be financed substantially through new debt, and a termination of its collaboration with Merck KGaA for Bavencio, with Pfizer to receive a 15% royalty on future sales.

Pfizer Inc. reported revenues of $22.6 billion for the third quarter of 2022, a 6% decrease year-over-year, primarily driven by lower sales of Comirnaty, partially offset by growth from Paxlovid. For the first nine months of 2022, revenues increased by 32% to $76.0 billion, largely due to strong performance from Paxlovid and Comirnaty. Net income attributable to Pfizer Inc. common shareholders was $8.6 billion for the quarter, up from $8.1 billion in the prior year. The company completed significant acquisitions, including Arena Pharmaceuticals for $6.6 billion and Biohaven for $11.5 billion, which are expected to bolster its pipeline. Despite a decrease in Comirnaty sales, Pfizer's overall financial health remains strong, supported by diversified product offerings and strategic business development. The company's liquidity position is robust, with significant operating cash flows and access to credit facilities. Pfizer continues to invest in research and development, with a notable increase in R&D expenses driven by the development of newly acquired assets and ongoing late-stage clinical programs. Investors should monitor the ongoing patent litigations and regulatory developments, particularly concerning the impact of the Inflation Reduction Act on drug pricing.

Pfizer Inc. reported strong financial results for the quarter and six months ended July 3, 2022. Total revenues surged by 47% and 60% respectively, primarily driven by substantial contributions from its COVID-19 products, Comirnaty and Paxlovid. Net income attributable to Pfizer Inc. common shareholders also saw significant increases, reflecting the strong revenue growth. The company's strategic acquisitions, including that of Arena Pharmaceuticals, are beginning to contribute, with integration costs noted. Pfizer continues to manage its diverse portfolio, with key products like Eliquis, Prevnar family, and Vyndaqel/Vyndamax showing robust operational growth, while some products like Xeljanz and Sutent experienced declines due to market dynamics and loss of exclusivity. The company also provided updated financial guidance for its COVID-19 related products, indicating continued significant revenue expectations for the remainder of the year. Pfizer remains focused on innovation and strategic business development, positioning itself for future growth.

Pfizer Inc. reported a substantial increase in revenues for the first quarter of 2022, reaching $25.7 billion, a 77% jump from the prior year's quarter. This growth was overwhelmingly driven by sales of its COVID-19 vaccine, Comirnaty, and its COVID-19 treatment, Paxlovid, which contributed significantly to both domestic and international markets. Net income attributable to Pfizer Inc. common shareholders also saw a significant increase, rising to $7.86 billion ($1.37 per diluted share) from $4.88 billion ($0.86 per diluted share) in the same period last year. The company also completed the acquisition of Arena Pharmaceuticals for $6.6 billion, adding new development-stage therapeutic candidates to its portfolio. While the core business demonstrated strong performance fueled by its COVID-19 products, Pfizer continued to invest in its R&D pipeline and manage its strategic transformation, which included restructuring charges and ongoing business development activities. The company reaffirms its full-year revenue guidance for Comirnaty and Paxlovid, indicating continued reliance on these products for growth.

Pfizer Inc. reported strong financial results for the nine months ended October 3, 2021, driven by significant revenue growth, primarily from its COVID-19 vaccine, Comirnaty. Total revenues surged by 91% to $57.7 billion compared to the same period in 2020. Excluding Comirnaty, operational revenue growth was still robust at 8%, indicating the strength of its broader product portfolio. The company also demonstrated healthy profitability, with net income attributable to Pfizer Inc. common shareholders increasing substantially to $18.6 billion for the nine-month period. This performance reflects effective cost management alongside increased sales, with R&D expenses growing to support pipeline advancement, including significant investments in COVID-19 related programs and collaborations. Pfizer's financial position remains strong, with substantial cash and investments, and the company continues to return value to shareholders through dividends.

Pfizer Inc. reported strong revenue growth for the second quarter and first six months of 2021, largely driven by significant contributions from the Pfizer-BioNTech COVID-19 vaccine (BNT162b2). Total revenues for the second quarter of 2021 surged by 92% year-over-year to $19.0 billion, and for the first six months by 68% to $33.6 billion. The company's operational performance, excluding the impact of foreign exchange, also showed substantial improvement, with revenues increasing by 86% in the second quarter and 64% in the first six months. This growth was primarily fueled by the BNT162b2 vaccine, which generated $7.8 billion in the second quarter and $11.3 billion in the first six months. Excluding the vaccine, operational revenue growth remained robust at 10% for the quarter and 9% for the year-to-date, demonstrating continued strength in key products like Eliquis, Vyndaqel/Vyndamax, and Inlyta, alongside growth in biosimilars and the Hospital segment. Net income attributable to Pfizer Inc. common shareholders was $5.6 billion for the second quarter ($0.99 per diluted share) and $10.4 billion for the first six months ($1.87 per diluted share). The company maintained a healthy balance sheet with total assets of $170 billion and total equity of $70.3 billion as of July 4, 2021. Pfizer also highlighted ongoing business development initiatives, including a significant collaboration with Arvinas, Inc. and the acquisition of Amplyx Pharmaceuticals, Inc., underscoring its commitment to strategic growth in innovative medicines and vaccines.

Pfizer Inc.'s first quarter 2021 results, ending April 4, 2021, demonstrate significant year-over-year revenue growth, largely driven by the BNT162b2 (Pfizer-BioNTech COVID-19 Vaccine). Total revenues surged by 45% to $14.6 billion, with the COVID-19 vaccine alone contributing $3.5 billion. Excluding the vaccine, operational revenue growth was a solid 8%, supported by strong performance in key products like Eliquis, Vyndaqel/Vyndamax, and Xeljanz, though partially offset by declines in Prevnar 13 and Ibrance. Net income attributable to Pfizer Inc. common shareholders also saw a substantial increase, reaching $4.9 billion, or $0.86 per diluted share, compared to $3.4 billion, or $0.60 per diluted share, in the prior year's first quarter. This growth reflects the strong revenue performance and improved equity security gains, despite higher operating expenses related to increased R&D for COVID-19 treatments and higher cost of sales associated with the vaccine. The company maintains a strong liquidity position, with substantial cash and short-term investments.

Pfizer Inc. reported revenues of $12,131 million for the third quarter of 2020, a decrease of 4% compared to the same period in the prior year, primarily driven by an 18% operational decline in the Upjohn segment due to Lyrica's U.S. loss of exclusivity and lower sales of Lipitor and Norvasc in China. The Biopharma segment, however, showed a 4% operational growth, supported by key brands like Ibrance, Eliquis, and Xeljanz. The company's net income attributable to Pfizer Inc. was $2,194 million, or $0.39 per diluted share, compared to $7,680 million, or $1.36 per diluted share, in the prior year's quarter. This significant year-over-year decrease in net income was largely due to the non-recurrence of a substantial gain from the Consumer Healthcare JV transaction in Q3 2019. The company also highlighted ongoing R&D efforts, including a collaboration with BioNTech for a COVID-19 vaccine candidate, and provided updated financial guidance for the full year 2020. The company is progressing with its planned combination of Upjohn with Mylan, expecting the transaction to close in November 2020.

Pfizer Inc.'s (PFE) Q2 2020 report shows a decline in revenue compared to the prior year, primarily due to the ongoing impact of the Consumer Healthcare joint venture divestiture and the continued loss of exclusivity for Lyrica in the U.S. The Biopharma segment demonstrated resilience with operational growth driven by key brands like Ibrance, Eliquis, and Xeljanz, as well as strong performance in rare disease treatments. However, the Upjohn segment experienced a significant revenue decrease, largely attributed to generic competition. Despite the revenue challenges, Pfizer reported a net income attributable to Pfizer Inc. of $3.426 billion, or $0.61 per diluted share. The company also provided updated financial guidance for 2020, anticipating total revenues between $48.6 to $50.6 billion and adjusted diluted EPS between $2.85 to $2.95. Pfizer highlighted its ongoing efforts to combat COVID-19 through collaborations and advancements in vaccine development.

Pfizer Inc. reported $12.03 billion in revenues for the first quarter of 2020, a decrease of 8% compared to the prior year period. This decline was primarily attributed to a 37% operational decrease in the Upjohn segment, largely due to the loss of exclusivity for Lyrica, partially offset by a 12% operational growth in the Biopharma segment. The company's net income attributable to Pfizer Inc. was $3.40 billion, or $0.61 per diluted share, down from $3.88 billion, or $0.68 per diluted share, in the first quarter of 2019. The company also provided an updated financial outlook for 2020, anticipating revenues between $48.5 billion and $50.5 billion, with adjusted diluted EPS in the range of $2.82 to $2.92. The report also highlighted ongoing business development activities, including a collaboration with BioNTech for a COVID-19 vaccine candidate and an agreement with Valneva SE for a Lyme disease vaccine candidate. The company's financial position remains solid, with cash and cash equivalents increasing to $2.15 billion. Pfizer continued its strategic transformation towards a more focused, science-based innovative medicines business, with the pending combination of Upjohn with Mylan to create Viatris expected to close in the second half of 2020. The company also detailed its response to the COVID-19 pandemic, emphasizing its commitment to developing treatments and vaccines, while also noting potential impacts on sales and clinical trials.

Pfizer Inc. reported strong financial performance for the nine months ended September 29, 2019. Total revenues for the period were $39.06 billion, a slight decrease of 2% from the prior year, impacted by foreign exchange rates. However, on an operational basis, revenues increased by 1%. Net income attributable to Pfizer Inc. saw a significant increase of 44% to $16.61 billion, largely driven by a substantial gain from the Consumer Healthcare joint venture transaction with GSK. Earnings per diluted share also grew significantly to $2.92. The company made strategic moves during the period, including the acquisition of Array BioPharma and Therachon Holding AG, bolstering its pipeline in oncology and rare diseases, respectively. Additionally, Pfizer announced its intention to combine its Upjohn business with Mylan, a move expected to create a new global pharmaceutical company. The balance sheet reflects increased debt to fund acquisitions, with total liabilities rising to $105.05 billion. Cash and cash equivalents increased to $2.79 billion. The company's financial position remains solid, supported by strong operating cash flows, though working capital saw a decrease due to strategic investments and the Consumer Healthcare JV transaction. Overall, Pfizer demonstrated resilience and strategic foresight, with significant one-time gains boosting net income while key acquisitions position the company for future growth. Investors should note the impact of ongoing strategic transactions and the company's robust R&D pipeline.

Pfizer Inc. reported total revenues of $13.26 billion for the second quarter of 2019, a slight decrease of 2% compared to the prior year quarter, largely due to unfavorable foreign exchange impacts. Despite the revenue dip, net income attributable to Pfizer Inc. saw a significant increase of 30% to $5.05 billion, driven by a favorable tax provision and lower costs. The company highlighted key strategic moves, including the completion of the Consumer Healthcare joint venture with GSK and the acquisition of Array BioPharma. Additionally, Pfizer announced an agreement to combine its Upjohn business with Mylan, signaling a significant restructuring aimed at optimizing its portfolio and focusing on its Biopharma segment. These strategic actions are expected to reshape Pfizer's future business landscape.

Pfizer Inc. reported strong first-quarter 2019 results, with revenues increasing by 2% to $13.1 billion and income from continuing operations rising by 9% to $3.9 billion compared to the prior year. Diluted earnings per share (EPS) also saw a significant increase of 15% to $0.68. The company's performance was driven by robust operational growth across key biopharmaceutical products such as Eliquis, Ibrance, Prevnar 13, and Xeljanz, which contributed significantly to the Biopharma segment's revenue growth. The Upjohn segment experienced a slight revenue decline, largely due to ongoing generic competition for products like Viagra and Lyrica, though operational growth in emerging markets provided some offset. Pfizer also continued its share repurchase program, buying back approximately $8.9 billion in stock during the quarter. Looking ahead, Pfizer reaffirmed its 2019 financial guidance, expecting revenues between $52.0 billion and $54.0 billion and adjusted diluted EPS between $2.83 and $2.93, reflecting underlying business strength and a positive outlook despite anticipated headwinds from patent expirations and generic competition. The company also remains focused on strategic initiatives, including the proposed combination of its consumer healthcare business with GSK.

Pfizer Inc. reported a notable increase in net income for the third quarter and first nine months of 2018 compared to the prior year, driven by significant favorable tax adjustments related to the Tax Cuts and Jobs Act (TCJA) and operational growth across key products. Revenues saw a modest 1% increase year-over-year for the third quarter, reaching $13.3 billion, and a 2% increase for the first nine months to $39.7 billion. This growth was primarily fueled by the Innovative Health (IH) segment, which saw strength in products like Eliquis, Ibrance, Xeljanz, and Prevnar 13, despite headwinds in some legacy products and therapeutic areas. The company's financial position remains strong with substantial cash and investments, although short-term and long-term debt remain significant. Pfizer also continued its share repurchase program, demonstrating a commitment to returning capital to shareholders. The company reiterated its full-year 2018 financial guidance, indicating confidence in its operational performance despite some downward revenue revisions due to foreign exchange rates and Essential Health performance.

Pfizer Inc. reported solid revenue growth in the second quarter and first six months of 2018, driven by operational improvements and favorable foreign exchange rates. The company saw strong performance in its Innovative Health (IH) segment, particularly from key brands like Eliquis, Ibrance, and Xeljanz, along with contributions from new product launches such as Eucrisa and advancements in its vaccine portfolio. The Essential Health (EH) segment experienced a slight revenue decline operationally, impacted by the ongoing transition of Viagra revenues and challenges in the sterile injectable portfolio, though this was partially offset by the shift of Viagra revenues and growth in biosimilars. Overall profitability improved significantly, with income from continuing operations before taxes showing a substantial increase year-over-year. This was driven by revenue growth, favorable changes in equity security valuations, increased income from collaborations, and a lower effective tax rate, partly due to the Tax Cuts and Jobs Act (TCJA) of 2017. Pfizer also maintained a strong cash flow from operations and continued its commitment to returning capital to shareholders through dividends and share repurchases.

Pfizer Inc. reported a 1% increase in total revenues for the first quarter of 2018, reaching $12.9 billion, driven by favorable foreign exchange rates and growth in key Innovative Health (IH) products like Ibrance and Eliquis. However, operational revenue saw a 2% decline, impacted by product losses of exclusivity and ongoing legacy Hospira product shortages impacting the Essential Health (EH) segment. Net income attributable to Pfizer Inc. rose by 14% to $3.6 billion, with diluted EPS increasing to $0.59 from $0.51 in the prior year. The company's effective tax rate significantly decreased to 13.5% from 20.8%, largely due to the U.S. Tax Cuts and Jobs Act (TCJA). Pfizer also continued its robust share repurchase program, buying back approximately $6.1 billion worth of stock in the quarter. The company reaffirmed its full-year 2018 financial guidance, projecting adjusted diluted EPS between $2.90 and $3.00.

Pfizer Inc. reported revenues of $13.17 billion for the third quarter of 2017, a slight increase of 1% year-over-year, and $38.84 billion for the first nine months of 2017, a 1% decrease. Net income attributable to Pfizer Inc. significantly increased to $2.84 billion in Q3 2017 from $1.36 billion in Q3 2016, reflecting strong operational performance and favorable tax items. The company's Innovative Health (IH) segment saw robust revenue growth of 11% driven by key products like Ibrance and Eliquis, while the Essential Health (EH) segment experienced a revenue decline of 12% due to loss of exclusivity and product shortages. Key financial highlights include a substantial increase in income from continuing operations before taxes, up 123% year-over-year for Q3, driven by higher revenues and lower cost of sales, including the non-recurrence of significant impairment charges from the prior year. The company also continued its share repurchase program, demonstrating a commitment to returning capital to shareholders. Pfizer's effective tax rate increased to 20.3% in Q3 2017 from 15.5% in Q3 2016, primarily due to changes in the jurisdictional mix of earnings.

Pfizer Inc. reported revenues of $12.9 billion for the second quarter of 2017, a 2% decrease compared to the same period in the prior year, impacted by foreign exchange rates and divested operations. Net income attributable to Pfizer Inc. rose to $3.1 billion, or $0.51 per diluted share, up from $2.0 billion, or $0.33 per diluted share, in the second quarter of 2016. This improvement was driven by lower cost of sales, reduced restructuring charges, and a favorable change in "Other (income)/deductions—net", largely due to the absence of significant legal settlements seen in the prior year. The Innovative Health (IH) segment saw revenue growth, boosted by key brands like Ibrance, Eliquis, and Xeljanz, while the Essential Health (EH) segment experienced a revenue decline due to product losses of exclusivity and the sale of its Hospira Infusion Systems business. For the first six months of 2017, revenues were $25.7 billion, also down 2% year-over-year. Net income attributable to Pfizer Inc. increased to $6.2 billion, or $1.02 per diluted share, from $5.1 billion, or $0.82 per diluted share, in the comparable prior-year period. The company continued its share repurchase program, with approximately $6.4 billion remaining authorization at the end of the quarter. Pfizer also reaffirmed its full-year financial guidance, with adjusted diluted EPS expected to be between $2.54 and $2.60.

Pfizer Inc.'s first quarter 2017 report shows a slight year-over-year revenue decline of 2% to $12.8 billion, impacted by one less selling day and unfavorable foreign exchange rates. Despite this, the company demonstrated solid operational performance with growth in key brands like Ibrance and Eliquis. Net income attributable to Pfizer Inc. increased by 3% to $3.12 billion, leading to a diluted EPS of $0.51, up from $0.49 in the prior year's quarter. The company continued to execute its business development strategy, with significant acquisitions in oncology and anti-infectives. Divestiture of the Hospira Infusion Systems net assets was completed. Management reaffirmed its 2017 financial guidance, indicating confidence in continued operational performance and strategic execution throughout the year. The report highlights ongoing R&D investments and cost-reduction initiatives aimed at driving long-term value.

Pfizer Inc. reported revenues of $13.05 billion for the third quarter of 2016, a 7.7% increase year-over-year, driven by operational growth and the inclusion of Hospira's results. Net income attributable to Pfizer Inc. for the quarter was $1.32 billion, down from $2.13 billion in the prior year, largely due to a $1.4 billion impairment charge related to the divestiture of the Hospital Infusion Systems (HIS) business and higher costs. For the nine months ended October 2, 2016, revenues increased by 12.6% to $39.20 billion, while net income attributable to Pfizer Inc. decreased by 11.2% to $6.36 billion. The company completed significant acquisitions during the period, including Medivation for approximately $14.3 billion and Anacor for approximately $4.9 billion, bolstering its oncology and dermatology portfolios respectively. Pfizer also announced its intention to divest its global infusion therapy net assets (HIS) to ICU Medical for approximately $1 billion. Management highlighted strong operational growth in key innovative health products like Ibrance and Xeljanz. However, the Essential Health segment faced continued pressure from the loss of exclusivity on several products. The company reaffirmed its financial guidance for the full year 2016, anticipating revenues between $52.0 and $53.0 billion. The report also details ongoing legal proceedings and restructuring charges related to acquisitions and cost-reduction initiatives.

Pfizer Inc. reported solid financial results for the second quarter and first half of 2016, demonstrating revenue growth and effective operational management. Total revenues increased by 11% year-over-year for the quarter and 15% for the first half, driven by strong performances in the Innovative Health (IH) segment, particularly from key products like Ibrance and Xeljanz, and the inclusion of Hospira's results in the Essential Health (EH) segment. Despite significant investments in acquisitions, including Anacor, and ongoing cost-reduction initiatives, Pfizer maintained healthy profitability. The company's strategic focus on key therapeutic areas and business development, alongside a commitment to capital allocation through share repurchases and dividends, positions it well for continued growth. Investors should note the impact of legacy Hospira operations and the potential for future strategic decisions regarding business segment separation.

Pfizer Inc. reported strong revenue growth of 20% to $13.0 billion for the first quarter of 2016 compared to the prior year. This growth was driven by the inclusion of Hospira operations and continued strong performance from key innovative products like Ibrance and Eliquis, as well as Prevnar/Prevenar 13. The company also saw significant increases in operating income, largely due to these revenue drivers and improved operational efficiencies, although cost of sales saw a substantial increase, partly due to the Hospira acquisition. Financially, Pfizer demonstrated robust operating cash flow and maintained a strong balance sheet. The company repurchased $5 billion of its common stock in the quarter and declared a cash dividend, signaling a continued commitment to returning capital to shareholders. Despite some challenges like foreign exchange headwinds and increased restructuring costs, the company reaffirmed its full-year financial guidance, indicating confidence in its business outlook and strategic execution.

Pfizer Inc. reported revenues of $12.1 billion for the third quarter of 2015, a slight decrease of 2% compared to the prior year, primarily impacted by unfavorable foreign exchange rates. Operationally, revenues saw a 6% increase, driven by strong performance from key innovative products like Prevnar 13, Ibrance, and Eliquis, as well as the inclusion of one month of Hospira's U.S. operations following its acquisition in September 2015. The company's income from continuing operations for the quarter was $2.1 billion, down 20% year-over-year, impacted by higher restructuring charges and asset impairments, although partially offset by a lower effective tax rate and reduced operating expenses. For the first nine months of 2015, total revenues decreased by 5% to $34.8 billion, with operational growth significantly hampered by an 8% unfavorable foreign exchange impact. Net income from continuing operations for the nine-month period was $7.1 billion, a 9% decrease from the previous year, also affected by increased restructuring and impairment charges, but benefiting from a lower effective tax rate and reduced cost of sales and administrative expenses. The company reaffirmed its full-year 2015 financial guidance, with an updated outlook for reported revenues and adjusted diluted EPS, reflecting the operational performance and the Hospira acquisition.

Pfizer Inc. reported a decrease in revenues for the second quarter and first six months of 2015 compared to the prior year, primarily due to unfavorable foreign exchange impacts, although operational performance showed some resilience. The company saw a revenue increase from key products like Prevnar 13, Eliquis, and Lyrica, but this was offset by the loss of exclusivity for significant drugs such as Celebrex and Zyvox. Despite the revenue headwinds, Pfizer is actively pursuing growth through strategic acquisitions, notably the pending acquisition of Hospira, which is expected to close in the second half of 2015 and contribute to future synergies. The company's financial position remains strong, supported by robust operating cash flows, allowing for continued investments in R&D and shareholder returns through dividends and share repurchases.

Pfizer Inc. reported revenues of $10.9 billion for the first quarter of 2015, a 4% decrease compared to the same period in 2014, primarily due to unfavorable foreign exchange impacts. Operationally, revenues saw a 2% increase, driven by strong performance of key products like Prevnar 13 and Eliquis, along with growth in emerging markets. However, this growth was offset by the loss of exclusivity for Celebrex and other products. Net income attributable to Pfizer Inc. was $2.38 billion, a slight increase from $2.33 billion in the prior year. The company highlighted a significant reduction in legal charges, which positively impacted earnings, but this was partially offset by higher research and development expenses and an increased effective tax rate. Pfizer also announced its intention to acquire Hospira for approximately $17 billion, expected to close in the second half of 2015, signaling a strategic move to expand its portfolio.

Pfizer Inc.'s Q3 2014 report shows a slight decrease in revenues compared to the previous year, primarily due to the loss of exclusivity for several key products and the expiration of collaboration agreements, which significantly impacted alliance revenues. Despite the revenue dip, the company managed to slightly increase its income from continuing operations, driven by factors like lower restructuring charges, favorable royalty-related income from Enbrel, and a lower effective tax rate. The company also highlighted growth in specific products like Lyrica, Prevnar, Xalkori, and Xeljanz, and positive performance in emerging markets, signaling a strategic shift towards innovation and growth areas. Looking ahead, Pfizer is focusing on its pipeline and business development initiatives, including the recent acquisition of InnoPharma and collaborations in oncology. The company reaffirmed its financial guidance for the full year 2014, demonstrating confidence in its strategic direction despite the ongoing challenges of patent expirations and a competitive market environment. Investors will be watching Pfizer's ability to drive growth from its newer products and R&D pipeline to offset revenue declines from mature products.

Pfizer Inc. reported a decrease in revenues for both the three-month and six-month periods ending June 29, 2014, compared to the prior year. This decline was primarily attributed to the loss of exclusivity for several key products, the expiration of co-promotion agreements (notably for Enbrel), and ongoing generic competition. Despite revenue challenges, the company demonstrated improved operational efficiency and a lower effective tax rate. Income from continuing operations saw a decrease primarily due to the non-recurrence of a significant patent litigation settlement gain in the prior year. However, adjusted income, which excludes certain one-time items and purchase accounting impacts, showed a substantial increase, indicating underlying operational strength. Pfizer continued its share repurchase program and paid dividends, reflecting a commitment to shareholder returns while managing costs through various initiatives.

Pfizer Inc. reported total revenues of $11.35 billion for the first quarter of 2014, a decrease of 9% compared to the same period in the prior year, primarily due to the expiration of co-promotion agreements and ongoing generic competition for key products like Lipitor and Viagra. Net income attributable to Pfizer Inc. also saw a decline, down 15% to $2.33 billion, impacted by higher legal charges and the non-recurrence of a gain from a prior-year asset transfer. However, the company maintained a strong financial position with robust operating cash flow and a significant amount of cash and short-term investments. Management highlighted cost-reduction initiatives and growth from newer products like Lyrica and Xeljanz as key drivers, while also facing challenges from patent expirations and an evolving regulatory landscape. The company also noted its ongoing consideration of a potential merger with AstraZeneca. For the quarter, Pfizer's effective tax rate significantly improved to 20.4% from 29.8% in the prior year, largely due to favorable resolutions of prior-year tax positions. This improvement, combined with lower operating expenses from cost-reduction efforts and reduced asset impairment charges, partially offset the decline in revenues and higher legal expenses. The company reaffirmed its previously issued adjusted financial guidance for 2014, indicating confidence in its ability to navigate the current market conditions and deliver on its financial targets.

Pfizer Inc.'s third-quarter and nine-month results for 2013 demonstrate a company navigating patent expirations and strategic divestitures while pursuing new growth areas. While overall revenues saw a slight decline year-over-year, driven by the loss of exclusivity for key products like Lipitor and ongoing collaboration expirations, the company reported a significant increase in income from continuing operations for the nine-month period. This improvement was largely due to substantial patent litigation settlement income and reduced legal charges, alongside favorable business development activities, including a significant gain on the Zoetis divestiture. Key financial shifts include a notable decrease in R&D expenses and selling, informational, and administrative costs, reflecting ongoing cost-reduction initiatives. The company's balance sheet shows a strong liquidity position, with substantial cash and short-term investments, despite increased share repurchases and dividend payments. Investors should note the substantial restructuring and acquisition-related costs impacting reported figures, and consider the company's adjusted income metrics for a clearer view of operational performance. Pfizer continues to manage its portfolio through strategic business development, focusing on key therapeutic areas and emerging markets.

Pfizer Inc. reported its financial results for the quarter and six months ended June 30, 2013. The company experienced a notable decrease in revenues, primarily attributed to the loss of exclusivity for key products like Lipitor in various markets, leading to increased generic competition. Despite the revenue decline, Pfizer managed to significantly boost its net income, largely driven by a substantial gain from the disposal of its Animal Health business (Zoetis) and a substantial patent litigation settlement income. The company's strategic divestitures, including Zoetis and the Nutrition business, are reshaping its portfolio, with a focus on streamlining operations and a commitment to future innovation. Operationally, Pfizer saw its income from continuing operations increase due to favorable legal settlements and cost-reduction initiatives, though these were partially offset by ongoing business challenges like loss of exclusivity and market competition. The company continued its share repurchase program, demonstrating a commitment to returning capital to shareholders, while also managing its debt effectively. Investors should note the significant impact of one-time events on the reported net income, while the core operational performance reflects the ongoing challenges and strategic adjustments within the pharmaceutical industry.

Pfizer Inc. reported total revenues of $13.5 billion for the first quarter of 2013, a decrease of 9% compared to the same period in 2012. This decline was primarily driven by the loss of exclusivity for key products like Lipitor, leading to a significant drop in branded revenue. Despite the revenue challenges, Pfizer demonstrated strong operational execution, with income from continuing operations increasing by 60% to $2.8 billion, mainly due to favorable legal settlements and lower restructuring charges compared to the prior year. The company also made significant progress in its strategic initiatives, including the initial public offering (IPO) of its Animal Health subsidiary, Zoetis, and the sale of its Nutrition business, which are expected to streamline its portfolio and focus on core biopharmaceutical operations. The company's financial performance in Q1 2013 was marked by a significant decrease in revenues, largely due to patent expirations and generic competition impacting major products such as Lipitor. However, profitability improved substantially year-over-year, driven by reduced operating expenses, lower restructuring charges, and a favorable legal settlement. The strategic divestiture of the Nutrition business and the partial IPO of Zoetis represent key steps in Pfizer's ongoing transformation, aiming to create a more focused biopharmaceutical company. Investors should monitor the impact of ongoing product exclusivity losses and the company's ability to drive growth from its pipeline and newer products.

Pfizer Inc.'s third-quarter 2012 filing reflects a period of significant revenue decline, primarily driven by the loss of exclusivity for its blockbuster drug Lipitor. Revenues for the quarter fell by 16% year-over-year to $14.0 billion, with an operational decline of 12%. This downturn was exacerbated by unfavorable foreign exchange rates. Despite the revenue challenges, Pfizer reported an increase in income from continuing operations to $3.1 billion, up from $2.3 billion in the prior year's quarter. This improvement was largely due to a substantial tax benefit of approximately $1.1 billion resulting from a settlement with the IRS, as well as reduced restructuring and acquisition-related costs compared to the previous year. The company is actively managing its portfolio, with plans to divest its Nutrition business to Nestlé and potentially spin off its Animal Health division. These strategic moves aim to streamline operations and focus on core biopharmaceutical strengths. Pfizer also continues to invest in research and development, focusing on five high-priority therapeutic areas, while also facing ongoing legal proceedings and patent litigation, which are detailed in the filing.

Pfizer Inc. reported a decrease in revenues for the second quarter and first six months of 2012 compared to the prior year, primarily due to the loss of exclusivity for key products like Lipitor, alongside unfavorable foreign exchange impacts. Despite the revenue decline, the company saw an increase in income from continuing operations, driven by lower operating expenses, including reduced cost of sales, selling, informational, and administrative expenses, and research and development costs. This was partially offset by increased charges related to certain legal matters. Key strategic initiatives include the planned IPO of its Animal Health business, Zoetis, and the sale of its Nutrition business to Nestlé, both expected in the first half of 2013. The company continued its share repurchase program and maintained its dividend payments, demonstrating a focus on returning capital to shareholders. Management remains confident in the company's liquidity and ability to meet its financial obligations despite the challenging global economic environment and industry-specific pressures.

Pfizer Inc. reported a 7% decrease in total revenues for the first quarter of 2012, reaching $15.4 billion compared to $16.5 billion in the prior year period. This decline was primarily driven by the loss of exclusivity for key products like Lipitor in the U.S. and unfavorable foreign exchange rates. Net income also saw a significant drop of 19% to $1.8 billion, or $0.24 per diluted share, down from $2.2 billion, or $0.28 per diluted share, in Q1 2011. The company incurred substantial "certain significant items" totaling $1.45 billion net of tax, largely due to higher litigation charges and asset impairment charges, which impacted profitability. Despite these challenges, Pfizer continued its portfolio transformation, announcing the sale of its Nutrition segment to Nestlé for $11.85 billion, expected to close in the first half of 2013. Looking ahead, Pfizer reaffirmed its commitment to strengthening its core businesses and enhancing shareholder value through dividends and share repurchases. The company's strategic focus remains on key therapeutic areas, and it is actively managing its R&D pipeline and cost structure to navigate the evolving pharmaceutical landscape. Investors should note the ongoing impact of patent expirations and the company's efforts to adapt to market changes.

Pfizer Inc. reported strong revenue growth of 7% for the third quarter of 2011, reaching $17.2 billion, primarily driven by key biopharmaceutical products like Lipitor and Lyrica, as well as favorable foreign exchange rates and the inclusion of King Pharmaceuticals. This growth was partially offset by the loss of exclusivity for several products and the impact of U.S. healthcare reform. Net income for the quarter saw a significant increase, benefiting from the absence of large impairment charges recorded in the prior year and a lower effective tax rate. The company also continues to manage its operations through various initiatives, including cost reductions and productivity improvements. Pfizer is actively exploring strategic alternatives for its Animal Health and Nutrition businesses, aiming to enhance shareholder value and sharpen its focus on core biopharmaceutical operations. The company reiterated its full-year 2011 financial guidance and provided 2012 targets, signaling confidence in its strategic direction despite ongoing industry and economic challenges.

Pfizer Inc.'s (PFE) second-quarter 2011 results show relatively stable revenues compared to the prior year, with $17.0 billion for the quarter and $33.5 billion for the first six months. While facing headwinds from patent expirations of key drugs like Lipitor and Effexor XR, and a reduction in revenue due to U.S. healthcare legislation, the company benefited from growth in products like the Prevnar franchise and Lyrica, along with favorable foreign exchange rates and the inclusion of King Pharmaceuticals. Net income from continuing operations increased year-over-year for both the quarter and the first six months, reaching $2.6 billion and $4.8 billion, respectively. This was driven by increased revenues, improved operating efficiency, and a significantly lower effective tax rate in 2011 compared to 2010. The company also made progress on strategic initiatives, including the sale of its Capsugel business and exploration of alternatives for its Animal Health and Nutrition segments. Despite ongoing patent challenges and a complex operating environment, Pfizer maintained a strong liquidity position.

Pfizer Inc. reported revenues of $16.5 billion for the first quarter of 2011, a slight decrease from $16.6 billion in the prior year period. This was primarily driven by lower revenues from legacy Pfizer products, partially offset by the inclusion of King Pharmaceuticals products and favorable foreign exchange. Net income attributable to Pfizer Inc. increased to $2.22 billion, or $0.28 per diluted share, from $2.03 billion, or $0.25 per diluted share, in the first quarter of 2010. This improvement was supported by a lower effective tax rate and reduced purchase accounting adjustments related to the Wyeth acquisition. The company completed the acquisition of King Pharmaceuticals for approximately $3.6 billion, significantly impacting balance sheet items and introducing new product lines. Pfizer also announced the agreement to sell its Capsugel business for $2.375 billion, with an expected closing in the third quarter of 2011. Significant restructuring charges related to R&D initiatives and ongoing legal matters, particularly hormone-replacement therapy litigation, also impacted the results.

Pfizer Inc.'s third quarter and first nine months of 2010 results were significantly impacted by the acquisition of Wyeth, which closed in October 2009. Revenues saw substantial year-over-year increases due to the inclusion of Wyeth's operations. However, income from continuing operations showed a sharp decline, primarily driven by significant charges including purchase accounting adjustments, asset impairments related to acquired intangibles, restructuring and acquisition-related costs, and a substantial charge for asbestos litigation. The company also experienced a higher effective tax rate in 2010 compared to 2009. Despite the reported net income decline, Pfizer highlighted "Adjusted Income" which excludes these significant items, showing growth. The company also detailed upcoming challenges, notably the loss of exclusivity for key drugs like Lipitor and Effexor XR, and the impact of the U.S. Healthcare Legislation. Looking ahead, Pfizer announced a definitive agreement to acquire King Pharmaceuticals and other strategic partnerships, demonstrating continued focus on business development.

Pfizer Inc. (PFE) reported its financial results for the fiscal quarter and six months ended July 4, 2010. The most significant event impacting these results was the acquisition of Wyeth on October 15, 2009. This acquisition significantly boosted revenues, showing an increase of 58% for the quarter and 56% for the six-month period compared to the prior year. This growth was driven by the inclusion of legacy Wyeth product revenues, alongside favorable foreign exchange rates and a modest increase from legacy Pfizer products. Despite the substantial revenue growth, net income for the six months decreased by 10% to $4.5 billion, largely due to increased expenses, including purchase accounting adjustments, restructuring and acquisition-related costs, and a higher effective tax rate. The company also highlighted the ongoing impact of the U.S. Healthcare Legislation enacted in March 2010, which is expected to continue to affect revenues and taxes. Pfizer is actively managing its costs and integrating the Wyeth acquisition, aiming for significant cost savings by 2012.

Pfizer Inc. reported first-quarter 2010 revenues of $16.8 billion, a significant 54% increase compared to the same period in 2009. This growth was primarily driven by the inclusion of $5.3 billion in revenues from the recently acquired Wyeth operations and a favorable foreign exchange impact of $733 million, partially offset by a slight decline in legacy Pfizer product revenues. However, net income attributable to Pfizer Inc. decreased by 26% to $2.0 billion, or $0.25 per diluted share, from $2.7 billion, or $0.40 per diluted share, in the prior year. This decline was attributed to increased expenses related to Wyeth integration, purchase accounting adjustments, higher restructuring and acquisition-related costs, increased interest expense, and a higher effective tax rate stemming from U.S. healthcare legislation changes and intangible asset amortization. Financially, Pfizer ended the quarter with total assets of $195.1 billion and total liabilities of $105.0 billion, resulting in shareholders' equity of $90.1 billion. The company's liquidity remains strong, with cash and cash equivalents totaling $1.8 billion, though short-term investments decreased significantly due to tax payments related to the Wyeth acquisition financing. Management reiterated 2010 financial guidance and adjusted 2012 revenue targets, reflecting the impact of the U.S. Healthcare Legislation.

Pfizer Inc. reported its third-quarter and nine-month results for the period ending September 27, 2009. For the quarter, revenues were $11.621 billion, a decrease of 3% from the prior year, while net income attributable to Pfizer Inc. rose 26% to $2.878 billion. For the first nine months, revenues decreased 7% to $33.472 billion, and net income remained relatively flat at $7.868 billion. The company finalized its acquisition of Wyeth for approximately $68 billion on October 15, 2009, a significant event not yet reflected in these interim financial statements but which will materially impact future results and the company's structure. Significant costs associated with this acquisition and ongoing cost-reduction initiatives were noted. The company's financial position was strengthened by substantial debt issuances to fund the Wyeth acquisition, leading to a significant increase in cash and investments. However, revenue declines were observed across major pharmaceutical products like Lipitor and Norvasc due to patent expirations and generic competition, further impacted by foreign exchange headwinds. Despite these challenges, Pfizer is actively managing its costs and strategically positioning itself for future growth through acquisitions and pipeline development.

Pfizer Inc. (PFE) reported its financial results for the second quarter and the first six months ended June 28, 2009. Total revenues saw a decrease of 9% year-over-year for both periods, largely attributed to foreign exchange headwinds and the loss of exclusivity for key drugs. Net income attributable to Pfizer Inc. also declined by 19% for the quarter and 10% for the six-month period, reflecting decreased revenues and higher costs associated with the pending acquisition of Wyeth, as well as increased tax expenses. The company is actively managing its operations through significant cost-reduction initiatives, aiming for approximately $3 billion in adjusted cost reductions by the end of 2011. Financially, Pfizer has strengthened its liquidity position, notably through the issuance of substantial senior unsecured notes to partially fund the pending $68 billion acquisition of Wyeth, which is expected to close by the end of the year. Despite the revenue challenges and the significant investments in the Wyeth acquisition, Pfizer is strategically repositioning its R&D focus and managing its operational costs.